Kidney Week

Abstract: PUB252

Etiology, Comorbidity, and Proteinuria Levels in Chinese Patients with CKD: A Real-World Cross-Sectional Study

Session Information

• Publication Only

Category: CKD (Non-Dialysis)

• 2202 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• Liu, Jian, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Jian Liu, MD

• Lu, Ninghao, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Ninghao Lu, MD

• Ouyang, Yan, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Yan Ouyang, PhD

• Lin, Xiaoling, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Xiaoling Lin, PhD

• Li, Xiao, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Xiao Li, MD, PhD

• Ren, Hong, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Hong Ren, MD

• Wang, Weiming, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Weiming Wang, MD

• Yerkintay, Guliya, AstraZeneca Investment China Co,.Ltd., Shanghai, China

Guliya Yerkintay, MS

• Zhao, Wenyan, AstraZeneca Investment China Co,.Ltd., Shanghai, China

Wenyan Zhao, MS

• Xie, Jingyuan, Department of Nephrology Institute of Nephrology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Jingyuan Xie, MD, PhD

Background

CKD etiology and comorbidity patterns are closely linked to proteinuria levels, but regional and population differences exist. Large-scale real-world data on etiology, comorbidity burden, and proteinuria levels in Chinese CKD patients are limited. This study describes etiologic distribution and analyzes comorbidity and treatment patterns by etiology and proteinuria level.

Methods

This planned cross-sectional study will use the Tianjin Healthcare Big Data Platform. We will identify adults with diagnosed CKD and available proteinuria measurements within 12 months before January 1, 2022. For patients without UACR but with UPCR, the Sumida 2020 formula will be used to estimate UACR equivalents. Patients will be stratified into four proteinuria groups: UACR <30, 30-299, 300-699, and ≥700 mg/g. Etiology will be classified using diagnostic codes and clinical records, including diabetic kidney disease, hypertensive nephropathy, glomerular diseases, and interstitial nephritis. Outcomes include proteinuria distribution by etiology, comorbidity prevalence, and treatment patterns. Descriptive statistics will analyze associations.

Results

The planned analysis will include approximately 274,249 CKD patients. Data analysis is ongoing, and detailed results will be available before October 2026. We anticipate a higher proportion of glomerular diseases than reported internationally, reflecting the CKD spectrum in China and helping address the data gap on severe proteinuria (UACR ≥700 mg/g) in glomerulonephritis. Proteinuria distribution is expected to vary by etiology, with glomerular diseases showing higher proteinuria levels and more moderate-to-severe proteinuria. Comorbidity burden is also expected to increase with proteinuria level. In particular, patients with UACR ≥300 mg/g may have higher prevalence of cardiovascular comorbidities and anemia than those with lower proteinuria.

Conclusion

This study will describe the association between etiology, comorbidity patterns, and proteinuria levels in a large real-world Chinese CKD cohort. The findings may support individualized management across CKD etiologies, improved use of novel renoprotective therapies, and enhanced cardiovascular risk management in patients with high proteinuria.